Status:

Do Not Prescribe (DNP), Red

Decision Date:

December 2020

Comments

RED^1,8

NICE TA658: Isatuximab with pomalidomide and dexamethasone, for treatment of relapsed and refractory multiple myeloma. (Decision date - December 2020)

NICE TA1098: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (decision date October 2025)

DO NOT PRESCRIBE (DNP)6: NICE TA727 - Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (Decision date  - Oct 2021)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again